EUVIMEDEUVIMED entdecken
Crossref

CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer

Wei Yan, Lin Qiu, Meiling Yang, Anran Xu, Manqi Ma, Qinzi Yuan, Xiaochen Ma, Wenjuan Liang, Xuenong Li, Yanxia Lu

Cancer Letters · 2023

DOI: 10.1016/j.canlet.2023.216263 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2023. Verfasst von Wei Yan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China; Department of Pathology, School of Basic Medi…. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Colorectal Neoplasms. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunotherapy and anti-EGFR targeted treatment occupying a pivotal position in colorectal cancer (CRC), is still limited to a group of patients who display specific molecular alterations and inevitably escape from resistance, further studies are still needed in colorectal cancer. We found that chemokine ligand 10 (CXCL10) expression correlates with intratumoral CD8+ T cell infiltration and reprograms tumor vasculatures in colorectal cancer. CXCL10 overexpression not only suppressed tumor growth but also increased CD8+ T cell infiltration and induced tumor vascular normalization in vivo. Additionally, the growth inhibition and tumor vascular normalization induced by CXCL10 can be reversed by the depletion of CD8+ T cells in vivo. Mechanically, CXCL10 interacts with VCAN to mediate tumor vascular normalization. The VCAN expression correlated inversely with the expression of CXCL10 and the infiltration of CD8+ T cells in CRC. Elevated CXCL10 expression sensitized colorectal cancer cells to cetuximab/anti-PD1 combination therapy compared with cetuximab or anti-PD1 alone. We propose that CXCL10 could be used to increase the anti-EGFR therapy and immunotherapy effect, targeting both tumor vessels and immune cells in colorectal cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesColorectal NeoplasmsHumansCetuximabProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsTumor MicroenvironmentImmunotherapyChemokine CXCL10

Stichwörter der Autor:innen

Anti-EGFRCXCL10ImmunotherapyVCANVascular normalization

Substanzen

CetuximabProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsCXCL10 protein, humanChemokine CXCL10

Autor:innen und Institutionen

  • Department of Pathology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, PR China; Department of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, Guangdong, PR Ch…
  • Medical Imaging Center, The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, PR China. Electronic address: jnuql@qq.com.
  • Biomaterials Research Center, School of Biomedical Engineering, Southern Medical University, Guangzhou, Guangdong, PR China. Electronic address: 1922136705@qq.com.

Förderung

  • National Natural Science Foundation of China
  • Basic and Applied Basic Research Foundation of Guangdong Province

Zitieren

APA

Yan, W., Qiu, L., Yang, M., Xu, A., Ma, M., Yuan, Q., Ma, X., Liang, W., Li, X., & Lu, Y. (2023). CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer. Cancer Letters. https://doi.org/10.1016/j.canlet.2023.216263

Vancouver

Yan W, Qiu L, Yang M, Xu A, Ma M, Yuan Q, et al. CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer. Cancer Letters. 2023. doi:10.1016/j.canlet.2023.216263

BibTeX
@article{Yan2023,
  author = {Yan, Wei and Qiu, Lin and Yang, Meiling and Xu, Anran and Ma, Manqi and Yuan, Qinzi and Ma, Xiaochen and Liang, Wenjuan and Li, Xuenong and Lu, Yanxia},
  title = {CXCL10 mediates CD8+ T cells to facilitate vessel normalization and improve the efficacy of cetuximab combined with PD-1 checkpoint inhibitors in colorectal cancer},
  journal = {Cancer Letters},
  year = {2023},
  doi = {10.1016/j.canlet.2023.216263}
}
Kostenlos starten →